Steward Partners Investment Advisory, LLC Summit Therapeutics Inc. Transaction History

Steward Partners Investment Advisory, LLC

$11 Billion
Q4 2024

A detailed history of Steward Partners Investment Advisory, LLC transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Steward Partners Investment Advisory, LLC holds 2,503 shares of SMMT stock, worth $50,285. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,503

Previous 1,603 56.14%

Holding current value

$50,285

Previous $35,000 25.71%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2024 Feb 06, 2025	BUY	$17.52 - $23.46 $15,768 - $21,114	900 Added 56.14%	2,503 $44,000
Q3 2024 Nov 14, 2024	BUY	$6.89 - $31.93 $11,044 - $51,183	1,603 New	1,603 $35,000
Q1 2024 May 15, 2024	BUY	$2.55 - $5.07 $16,575 - $32,955	6,500 Added 1.08%	606,500 $2.51 Million
Q4 2023 Feb 12, 2024	SELL	$1.67 - $2.83 $83,500 - $141,500	-50,000 Reduced 7.69%	600,000 $1.57 Million
Q3 2023 Nov 13, 2023	BUY	$1.54 - $2.42 $77,000 - $121,000	50,000 Added 8.33%	650,000 $1.22 Million
Q2 2023 Aug 14, 2023	SELL	$1.32 - $2.81 $40,352 - $85,901	-30,570 Reduced 4.85%	600,000 $1.51 Million
Q1 2023 May 15, 2023	BUY	$1.38 - $5.41 $449,286 - $1.76 Million	325,570 Added 106.74%	630,570 $1.1 Million
Q4 2022 Feb 15, 2023	BUY	$0.68 - $5.31 $207,400 - $1.62 Million	305,000 New	305,000 $1.3 Million
Q3 2021 Nov 12, 2021	SELL	$4.83 - $8.27 $9,660 - $16,540	-2,000 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$3.25 - $6.0 $6,500 - $12,000	2,000 New	2,000 $9,000

Others Institutions Holding SMMT

# of Institutions

233

Shares Held

83.1M

Call Options Held

1.66M

Put Options Held

2.56M

View Full List

About Summit Therapeutics Inc.

Ticker SMMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,215,008
Market Cap $4.04B
Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...

More about SMMT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Steward Partners Investment Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Steward Partners Investment Advisory, LLC with notifications on news.

Account

Steward Partners Investment Advisory, LLC Summit Therapeutics Inc. Transaction History